CD8A and neoplasm: Immune checkpoint inhibitor (ICI)-based immunotherapy relies on the ability of CD8+ T cells to induce anti-tumour immune effects in CC, with tumour immune escape being manifested after the inhibition of CD8+ T cell activation (7, 8).